Table 1.
Demographic, clinical and laboratory characteristics of AML patients
| Normal range | Patients (n = 69) | |
|---|---|---|
| Age (years) | 59 ± 16 | |
| Gender | ||
| Male | 42 (61%) | |
| Female | 27 (39%) | |
| AML | ||
| Primary | 56 (81%) | |
| M0/M1/M2 | 32 | |
| M3 (APL) | 5 | |
| M4/M5 | 19 | |
| M6/M7 | 0 | |
| Secondary | 13 (19%) | |
| Post MDS | 12 | |
| Post MPN | 1 | |
| Peripheral blasts (103/µL) | 12 (2–30) | |
| Platelets (103/µL) | 150–400 | 47 (25–88) |
| Hemoglobin (g/dL) | 12.3–15.3 | 9.6 ± 1.9 |
| Prothrombin time (%) | 80–130 | 79 ± 23 |
| Fibrinogen (g/L) | 1.8–4.0 | 4.3 ± 2.3 |
| D-dimer (mg/L) | 0.0–0.5 | 5.1 (1.6–22.1) |
| LDH (U/L) | 84–246 | 474 (339–884) |
Data are presented as mean ± standard deviation or as median and interquartile range. AML subtypes are according to the French–American–British (FAB) classification.
APL acute promyelocytic leukemia, LDH lactate dehydrogenase, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasia.